Compare SFIX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | FULC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.9M | 535.5M |
| IPO Year | 2017 | 2019 |
| Metric | SFIX | FULC |
|---|---|---|
| Price | $3.84 | $8.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.50 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 2.1M | 907.5K |
| Earning Date | 03-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.44 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,226,505,000.00 | N/A |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.52 | N/A |
| 52 Week Low | $2.87 | $3.17 |
| 52 Week High | $5.92 | $15.74 |
| Indicator | SFIX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 56.51 |
| Support Level | $3.01 | $6.35 |
| Resistance Level | $5.78 | $9.99 |
| Average True Range (ATR) | 0.23 | 0.51 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 86.58 | 100.00 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.